Revefenacin is not currently available as a generic drug [1]. It is marketed under the brand name Enablex [2].
Why is Revefenacin not yet generic?
The patent protection for Enablex, the brand-name version of revefenacin, is still in effect [1]. Drug patent expiry dates determine when generic versions can be manufactured and sold [1]. Information on the specific patent expiry for revefenacin can be found on DrugPatentWatch.com [1].
When might Revefenacin become available as a generic?
The availability of a generic version of revefenacin will depend on when its patent protection expires. Until that time, only the branded drug, Enablex, can be legally marketed [1].
What is Revefenacin used for?
Revefenacin is a medication used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults [2]. It works by relaxing the bladder muscle, which helps to reduce the sudden urges to urinate [2].
How does Revefenacin compare to other overactive bladder treatments?
Revefenacin is an antimuscarinic medication. Other antimuscarinics used for OAB include oxybutynin, tolterodine, and solifenacin [3]. These medications share a similar mechanism of action in relaxing the bladder muscle but may differ in their side effect profiles and effectiveness for individual patients [3]. Other treatment approaches for OAB include behavioral therapies and other classes of medication [3].
What are the potential side effects of Revefenacin?
Common side effects of revefenacin can include dry mouth, constipation, blurred vision, and urinary tract infections [2]. More serious side effects are rare but can occur [2].
What is the typical cost of Enablex?
The cost of Enablex can vary depending on insurance coverage and pharmacy pricing [4]. As a branded medication without generic competition, it is generally more expensive than generic alternatives for other OAB treatments [4].
Are there any ongoing legal challenges related to Revefenacin patents?
Information regarding specific patent litigation for revefenacin is not readily available in the provided context but can be explored through specialized patent databases [1].
Sources:
[1] DrugPatentWatch.com
[2] Enablex Prescribing Information
[3] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[4] GoodRx